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Background: Pyoderma Gangrenosum,
acne, and hidradenitis suppurative syndrome
is a rare inherited disease syndrome
that encompasses features of pyoderma
gangrenosum (PG), nodulocystic acne,
and hidradenitis suppurativa (HS). These
three diseases share common mechanisms
consisting of overactivation of the innate
immune systems, resulting in ‘sterile’
neutrophilic dermatoses. Due to its
pronounced cutaneous presence, PASH
significantly alters quality of life. Currently,
treatment options are limited and aimed
at targeting the inflammatory cytokines
propagating the disease.
Case: A 28-year-old female with a past
medical history significant for PG, HS, and
tobacco use presented to the emergency
department for evaluation of worsening lower
extremity wounds and draining abscesses
of the left breast and axilla (Figure 1). The
patient’s HS had previously been well
controlled on Humira until discontinuing 1
year ago after resolution of her symptoms.
The patient was admitted to the hospital
due to concern for necrosis and super
infection. The inpatient dermatology team
was consulted to evaluate for recurrence of
PG. The team’s assessment of the patient’s
presentation was consistent with PASH
syndrome. An appropriate treatment plan was
recommended, and the patient was discharged
in stable condition with plans to follow-up
with outpatient dermatology to reinitiate
Humira. Patient consent was obtained to use
this case for educational purposes.

Figure 1. The patient demonstrated the three disease features that comprise PASH syndrome:
Nodulocystic facial acne (upper left), hidradenitis suppurativa of the axilla (lower left), and pyoderma
gangrenosum of the left lower extremity and left breast (upper and lower right, respectively).

Conclusion: This case highlights how
biologic drugs targeting key inflammatory
cytokines in the innate immunity pathway can
result in disease remission of PASH syndrome,
while lack of such agents can result in relapse
and exacerbation of the disease state. In
addition to this case, we will review the
overlapping neutrophilic dermatoses, PASH,
PAPA, and PAPASH, as well as their reported
treatment options. 
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